<DOC>
	<DOC>NCT02295813</DOC>
	<brief_summary>The purpose of this study is to assess the clinical and laboratory safety and to determine the pharmacokinetic profile of FBF001.</brief_summary>
	<brief_title>Safety and Pharmacokinetics Study of FBF001</brief_title>
	<detailed_description />
	<mesh_term>Influenza in Birds</mesh_term>
	<criteria>subject between 2140 years old with body mass index in the range 18 to 30 Kg/m2 Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness Any vaccination within three months before the inclusion Any vaccination against H5N1 virus Planned receipt of any vaccine during the study Any infectious disease within the month before the inclusion Any history of animal proteins allergy, animal allergy and/or any drug, food and pollen allergy Who has received blood or plasma derivatives (human or animal) in the three months preceding the initiation of the study Any medication within 14 days before the inclusion or within 5 times the elimination halflife or pharmacodynamic halflife of that drug</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>